NCT04340882View on ClinicalTrials.gov

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2030

Conditions
Metastatic Non-Small Lung Cell CancerRecurrent Non-Small Lung Cell CancerStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
DRUG

Docetaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Ramucirumab

Given IV

Trial Locations (2)

30303

Grady Health System, Atlanta

30322

Winship Cancer Institute of Emory University, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Emory University

OTHER